Warrior Trading

About the Author Warrior Trading

I launched Warrior Trading (formally Day Trade Warrior) in 2012, to help traders find their way to success. I set out with two simple goals. The first was to provide a hub where traders could come together to exchange ideas in a safe and moderated environment, and the second was to provide educational content for new traders. There were already other established day trading chat rooms, but I felt that none provided the type of market education that new traders need in order to be successful. This was based on my first hand experience of struggling to learn to trade, back in 2010. I lost over $30,000 making completely avoidable mistakes in my first year of trading. I know what it’s like to struggle as a beginner trader and to feel like all the odds are against you.

Plasmatech Biopharmaceuticals Inc (PTBI) Is Spiking Even Higher


Plasmtech Biopharmaceuticals Inc (NASDAQ:PTBI) is spiking higher by over 60% on news that the Company has agreed to acquire Abeona Therapeutics in common stock and cash.

PTBi_001

PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company, develops protein biologic therapies and oncology supportive care products. The company’s marketed product comprises MuGard the management of oral mucositis; and ProctiGard for the treatment of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region. It also develops CobOral, a mediated oral delivery technology that utilizes the body’s natural vitamin B12 transport system in the gut; and CobaCyte, a mediated targeted delivery technology that has application in in tumor targeting. The company was formerly known as Access Pharmaceuticals, Inc. and changed its name to PlasmaTech Biopharmaceuticals, Inc. in October 2014. PlasmaTech Biopharmaceuticals, Inc. is based in Dallas, Texas. – Yahoo Finance

Yesterday, Activist investor George Soros revealed his 5% passive stake in the company which boosted shares by over 100% in yesterday’s trading.

The Chief Executive Officer, Steven H. Rouhandeh said, “We believe this acquisition represents an exciting cornerstone of our strategy to build a world class cell and gene therapy company focused on rare diseases.”

The Chief Executive Officer of Abeona Therapeutics noted, “We are excited about building the future together, and believe this is just the first of many steps to building a comprehensive product pipeline in the rare disease space. PlasmaTech is currently developing a new generation plasma processing technology which enables and validates orphan proteins requiring periodic treatments.”